Results 11 to 20 of about 2,545 (184)
Mediterranean Journal of Hematology and Infectious Diseases, 2014 Patients with Hodgkin lymphoma treated with DNA-breaking alkylating agents such as mechlorethamine and procarbazine in the MOPP regimen and with topoisomerase II inhibitors, such as etoposide did show a long-term risk of developing therapy-related ...
Ercole Brusamolino +2 more
doaj +1 more source
Phase 1 Dose Escalation of Single-Agent Mechlorethamine in Dogs With Lymphoma. [PDF]
Vet Comp OncolABSTRACT Mechlorethamine is commonly prescribed to dogs at 3 mg/m2. The minimal toxicity observed indicates that higher doses of mechlorethamine are likely tolerable. The primary objective of this study was to determine the maximally tolerated dose (MTD) of mechlorethamine in dogs with lymphoma.
Chadsey LE, Hess PR, Intile JL.
europepmc +2 more sources
Archives of Dermatology, 1977 Six patients with mycosis fungoides were treated with topical mechlorethamine hydrochloride for periods of two to four years. Clinical and histological studies for radiomimetic and radiodermatitis-like effects failed to demonstrate any abnormalities.
Norman M. Price
openaire +3 more sources
Mechanistic Insights and Pharmacological Approaches for Nitrogen and Sulfur Mustards and Their Implications as Therapeutic Agents. [PDF]
J Appl ToxicolABSTRACT Nitrogen and sulfur mustards, often acting as vesicants, have significant consequences for public health. Skin is a common site for exposure to these vesicants that can result in considerable morbidity and mortality. Given that the treatment options are limited, new insights into the mechanisms for the toxicity of these vesicants that can be ...
Owens M +3 more
europepmc +2 more sources
Frontiers in Medicine, 2021 Topical chlormethine yields high response rates in mycosis fungoides cutaneous T-cell lymphoma with early discontinuation often attributed to skin reactions.
Christiane Querfeld +5 more
doaj +1 more source
Management of Mycosis Fungoides With Chlormethine Hydrochloride Gel in Combination With Systemic Therapies: A Case Series. [PDF]
Case Rep Dermatol MedBackground Mycosis fungoides (MF) is a subtype of T‐cell lymphoma that is characterised by the infiltration of malignant T cells into the skin. Treatment approaches usually include skin‐directed therapies for early‐stage disease and, additionally, systemic therapies for advanced stages.
Dobos G +6 more
europepmc +2 more sources